Healthcare Providers and Services
Company Overview of St. Michael's Hospital
St. Michael's Hospital operates as a hospital that provides various healthcare services to patients in Canada. It offers physical, emotional, and spiritual care services for patients and their families; various onsite services; and specialized programs, clinics, inpatient care units, and professional services, as well as tests, labs, and imaging services. The company also operates a teaching and research hospital for students from nursing, research, medicine, and health disciplines. St. Michael's Hospital was founded in 1892 and is based in Toronto, Canada.
30 Bond Street
Toronto, ON M5B 1W8
Founded in 1892
Key Executives for St. Michael's Hospital
Chief Executive Officer, President and Director
President of St Michael's Foundation
Chief Administrative Officer and Executive Vice President
Chief Medical Officer and Executive Vice President
Chief Nursing Executive and Executive Vice President of Programs
Compensation as of Fiscal Year 2015.
St. Michael's Hospital Key Developments
Edge Therapeutics Announces Multi-Year Research and Discovery Collaboration with St. Michael's Hospital
Nov 18 14
Edge Therapeutics announced a multi-year research and discovery collaboration with St. Michael's Hospital. The collaboration will focus on new therapeutic approaches for the treatment of various acute neurological conditions resulting from neurovascular instability. This discovery collaboration brings together Edge's scientific expertise in neurovascular disease with the research and high-throughput drug screening resources of St. Michael's Hospital. Initially the collaboration will focus on using validated models of intracerebral hemorrhage, cavernous malformations, and traumatic brain injury developed by St. Michael's to rapidly screen libraries of compounds for therapeutic activity, and to identify and optimize lead candidates for Edge's early stage pipeline. As previously announced, Edge Therapeutics has initiated patient enrollment in the third cohort of its NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of its lead product candidate EG-1962. The NEWTON study is evaluating the safety, tolerability and pharmacokinetics of EG-1962 compared to the current standard of care, oral nimodipine, in patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge is also investigating a second compound, EG-1964, for prevention of recurrence of chronic subdural hematoma. The company plans to submit an IND for that treatment in 2015.
St. Michael's Hospital Installs CARESTREAM Mobile X-Ray Systems to Enhance Care in Trauma, ICU Areas
Mar 12 14
St. Michael's Hospital recently installed two CARESTREAM DRX-Revolution Mobile X-ray Systems to deliver the benefits of wireless digital radiography in key areas throughout the hospital. One DRX-Revolution replaced an older CR X-ray room in the hospital's Level 1 Trauma Centre, and the other DRX-Revolution captures X-ray images of ICU and inpatients. Each DRX-Revolution is equipped with high-resolution CARESTREAM DRX-1C and DRX 2530C cesium iodide detectors. The CARESTREAM DRX-Revolution Mobile X-ray System features a small footprint, exceptional maneuverability, and an easy-to-use interface. In addition to bedside imaging, the new Carestream mobile system is used in the emergency department for trauma imaging using dedicated trauma stretchers.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|